Canopy Growth stock tumbles after announcing $200 million share sale plan
Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), a biotechnology company currently showing signs of being undervalued according to InvestingPro analysis, sold a total of 29,990 shares of common stock on August 11, 2025, for approximately $1.46 million. The sales occurred in multiple transactions with prices ranging from $47.40 to $49.44 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 16, 2024. Following the sales, Cheng directly owns 490,757 shares of Akero Therapeutics. Gain deeper insights into insider trading patterns and 12+ additional ProTips with InvestingPro, where expert analysis reveals that insider ownership remains substantial at over 15% of shares outstanding.
In other recent news, Akero Therapeutics has been the focus of several analyst updates and clinical developments. Akero’s recent presentation at the European Association for the Study of the Liver (EASL) highlighted positive results from a placebo-controlled study on F4 cirrhosis, showcasing the potential of their FGF21 therapy. This has led Jefferies to maintain a Buy rating with a $75 price target, noting the therapy’s robust data and potential market opportunity. Similarly, Citi has maintained a Buy rating but adjusted their price target to $78 after Akero disclosed its first quarter 2025 earnings and detailed clinical data from the Phase 2b SYMMETRY trial. The trial showed dose-dependent improvements in liver fibrosis metrics, further supporting the efficacy of efruxifermin.
TD Cowen has initiated coverage on Akero with a Buy rating and a $76 price target, emphasizing the strong efficacy data of Akero’s FGF21 analog, efruxifermin. Meanwhile, Morgan Stanley reiterated an Overweight rating with an $84 price target, following Novo Nordisk’s decision to discontinue its MASH treatment, which strengthens Akero’s competitive position. These developments collectively underscore a positive outlook from analysts on Akero Therapeutics’ potential in the MASH treatment space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.